Clinical Trial

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-13.
Status change: Not Yet Recruiting → Recruiting 2025-05-13
Trial Details
NCT Number NCT06092047
Lead Sponsor PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborators: Anhui Provincial Hospital
Conditions CD19-positive Relapsed or Refractory B-cell Malignancies
Enrollment 10 participants
Start Date 2023-10-01
Primary Completion 2026-07 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-05-16